{{cart_num}}
My CartCAS：557795-19-4
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：Light yellow to yellow Solid
Qty：
Size：
| CAS | 557795-19-4 |
| Name | Sunitinib |
| Molecular Formula | C22H27FN4O2 |
| Molecular Weight | 398.47 |
| Solubility | Soluble in DMSO ≥25mg/mL |
| Purity | HPLC≥98% |
| Appearance | Light yellow to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD08273555 |
| SMILES | O=C(NCCN(CC)CC)C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)F)=O)=C1C)C |
| Target Point | VEGFR;PDGFRβ |
| Passage | Angiogenesis;Protein Tyrosine Kinase/RTK |
| Background | Sunitinib is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR2 and PDGFRβ. |
| Biological Activity | Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2]. |
| In Vitro | Sunitinib Malate is also a good inhibitor of KIT and FLT-3[1]. In RS4;11 cells(FLT3-WT)，treatment with Sunitinib(SU11248)inhibits FLT3-WT phosphorylation in a dose-dependent manner with IC50 of approximately 250 nM. In MV4;11 cells that express FLT3-ITD，Sunitinib inhibits FLT3-ITD phosphorylation in a dose-dependent manner with an IC50 of 50 nM following a 2-hour treatment[3].In biochemical assays，Sunitinib(SU11248)exhibits competitive inhibition(with regard to ATP)against Flk-1 and PDGFRβ with Ki values of 9 nM and 8 nM，respectively. Sunitinib is also a competitive，albeit less potent，inhibitor of FGFR1 tyrosine kinase activity，with a Ki value of 0.83 μM. In addition to these three structurally related split kinase domain RTKs，the activity of Sunitinib has also been evaluated against a broad panel of additional tyrosine and serine/threonine kinases. In these biochemical assays，the IC50 values for Sunitinib are generally at least 10-fold higher than those for Flk-1 and PDGFR(e.g.，IC50values of: >10 μM for EGFR and Cdk2; 4 μM for Met; 2.4 μM for IGFR-1; 0.8 μM for Abl; and 0.6 μM for Src)[4]. |
| In Vivo | Sunitinib Malate has very good oral bioavailability，is highly efficacious in a number of preclinical tumor models，and is well tolerated at efficacious doses[1]. Sunitinib(80 mg/kg/day)inhibits the growth of established SF763T and Colo205 tumor xenografts in athymic mice. Sunitinib(SU11248)treatment effectively inhibits the growth of established tumor xenografts[4]. |
| Cell Experiment | RS4;11 and MV4;11 cell lines are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib(1 nM，5 nM，10 nM，25 nM，75 nM，100 nM，250 nM，500 nM)and FL(50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay in triplicate for each condition，as described by the manufacturer. Trypan blue cell viability assays are performed in parallel and yielded similar results[3]. |
| Animal Experiment | Mice[2] Female nu/nu mice(8-12 weeks old，25 grams)are used. Briefly，3-5×106 tumor cells are implanted s.c. into the hind flank region of mice on day 0. Daily treatment of tumor-bearing mice with oral administration of Sunitinib as a carboxymethyl cellulose suspension or as a citrate buffered(pH 3.5)solution is initiated once the tumors reached the indicated average size. Tumor growth is evaluated based on twice-weekly measurement of tumor volume. Typically，studies are terminated when tumors in vehicle-treated animals reach an average size of 1000 mm3 or when the tumors are judged to adversely effect the well being of the animals. Rats[4] Adult male Wistar rats(325-349 g)are used. To validate the ability of the time-lapse imaging method to evaluate the anti-angiogenic effects for a given drug treatment，two drug studies are conducted. In the first study，mesenteric windows are harvested from adult male Wistar rats and cultured for 3 days according to the two experimental groups: 1)10% serum(n=8 tissues from 4 rats)，and 2)10% serum+Sunitinib(5 μM; n=8 tissues from 4 rats). |
| Data Literature Source | [1]. Sun L，et al. Discovery of 5-[5-fluoro-2-oxo-1，2- dihydroindol-(3Z)-ylidenemethyl]-2，4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide，a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003 Mar 27;46(7):1116-9. [2]. Ali MM，et al. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J. 2011 Mar 2;30(5):894-905. [3]. O'Farrell AM，et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. [4]. Mendel DB，et al. In vivo antitumor activity of SU11248，a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Can |
| Unit | Piece |
| Specification | 50mg 10mM*1mL in DMSO 100mg 200mg |
是一种多靶点受体酪氨酸激酶抑制剂，抑制VEGFR2 和 PDGFRβ 。
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Manual Download
